DUN T1

Company Overview

Snapshot

Founded in July 2017 by Daniella Givon, Raanan Margalit, and Nadav Shraibom, DUN T1 operates with 1–10 employees. The company has secured $45K in total capital across one funding round from Fundit. DUN T1 is focused on developing an orally administered drug for type 1 diabetes, holding a patent for its novel natural ingredient.

Business overview

DUN T1 is an early-stage R&D company specializing in the development of an orally administered drug for type 1 diabetes. The company's core technology centers on a patented, natural active ingredient designed to offer a proactive approach to treatment. Operating within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development, DUN T1 serves markets focused on patients and pharmaceutical companies, aiming to address chronic diseases like diabetes.

Company Intelligence Q&A

When was DUN T1 founded and by whom?

DUN T1 was founded in July 2017 by Daniella Givon, Raanan Margalit, and Nadav Shraibom.

What is DUN T1's primary focus?

DUN T1 is an R&D company developing an orally administered drug for type 1 diabetes, utilizing a patented natural ingredient.

How many employees does DUN T1 currently have?

DUN T1 currently has 1–10 employees.

What is the total capital raised by DUN T1?

DUN T1 has raised a total of $45K.

What is DUN T1's vision regarding diabetes treatment?

DUN T1's vision is to develop a proactive approach towards the treatment and early diagnosis of type 1 diabetes.